LAUSR

on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 (last accessed 10 March 2021). 3 World Health Organization. Information note on COVID-19 and NCDs. 23 March 2020. Available at: https://www.who.int/publica tions/m/item/covid-19-and-ncds (last accessed 10 March 2021). 4 Gianfrancesco M, Hyrich KL, Al-Adely S et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79:859–66. 5 Mahil SK, Dand N, Mason KJ et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study. J Allergy Clin Immunol 2020; 147:60–71. 6 Mahil SK, Yates M, Langan S et al. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol 2021; 185:80–90.